Abstract: FR-PO0350
Trends in New Antidiabetes Drug Dispensation in Colombia, 2015-2023
Session Information
- Diabetic Kidney Disease: Progression, Predictive Tools, Therapeutics, and Outcomes
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 702 Diabetic Kidney Disease: Clinical
Authors
- Gonzalez, Camilo A., Hospital Universitario San Ignacio, Bogotá, Colombia
- Gomez, Maria Alejandra, Pontificia Universidad Javeriana Facultad de Medicina, Bogotá, Colombia
- Amador, Joan S, Pontificia Universidad Javeriana Facultad de Medicina, Bogotá, Colombia
- Garcia, Paola, Hospital Universitario San Ignacio, Bogotá, Colombia
- Castañeda-Gómez, María Camila, Pontificia Universidad Javeriana Facultad de Medicina, Bogotá, Colombia
- Contreras, Kateir, Hospital Universitario San Ignacio, Bogotá, Colombia
Background
Diabetes mellitus (DM) is an escalating global health burden and a major risk factor for cardiovascular and kidney diseases. Pharmacological management is fundamental for controlling DM and preventing complications, particularly with the emergence of new therapeutic classes offering proven cardiovascular and renal benefits. This study aims to describe trends in the dispensing of novel antidiabetic drugs with cardio-protective and reno-protective effects for DM treatment in Colombia between 2015 and 2023
Methods
A retrospective observational descriptive study was conducted. The primary data source was the Drug Price Information System (SISMED in Spanish), from which records of dispensed units of antidiabetic medications (monotherapies and combinations) were obtained. The quantities were converted to milligrams per quarter and year to calculate prescription rates, expressed as Defined Daily Dose (DDD) coefficients per 1,000 inhabitants per day, adjusted using WHO DDD coefficients.
Results
The analysis reveals a significant transformation of the therapeutic landscape. The exponential growth of SGLT2 inhibitors (iSGLT2) stands out; dapagliflozin and empagliflozin saw dramatic increases from 2018, reflecting broad clinical acceptance driven by evidence of their cardiovascular and renal benefits. This evolution coincide with the consolidation of evidence and guidelines. Although trends align with high-income countries, the speed of adoption in Colombia appears more moderate, influenced by economic and regulatory factors.
Conclusion
A rapid paradigm shift is observed towards the accelerated adoption of innovative SGLT2 inhibitors and GLP-1 agonists. Although this transition promises to improve clinical outcomes, it also highlights persistent challenges in access and cost sustainability in the Colombian context. These findings quantify this crucial change, underscoring the need for strategic pharmacovigilance and dynamic health policies to balance innovation and equity.